Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats
- PMID: 36150464
- DOI: 10.1016/j.lfs.2022.120966
Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats
Abstract
Aims: Liver cirrhosis defines by regenerative nodules and fibrotic septa, causing a complication called cirrhotic cardiomyopathy (CCM) with chronotropic hypo-responsiveness. In addition to lowering cholesterol levels, statins yield antioxidant and anti-inflammatory effects. In liver diseases animal models, statins have been shown to decrease hepatic inflammation, fibrogenesis, and portal pressure (PP). Therefore, we evaluated the atorvastatin effect on the heart in cirrhotic rats.
Materials and methods: Bile duct ligation (BDL) or sham operation performed on male Wistar rats and grouped as cirrhotic; BDL/Saline, BDL/Ator-7d(days) (Atorvastatin 15 mg/kg/day), and BDL/Ator-14d groups, or control; Sham/Saline, Sham/Ator-7d, and Sham/Ator-14d groups. Corrected QT interval (QTc interval), chronotropic responses, serum brain natriuretic peptides (BNP), heart tumor necrosis factor-α (TNF-α), nuclear factor erythroid 2-related factor 2 (Nrf2), and malondialdehyde (MDA) levels were studied along with atrial Ras homolog family member A (RhoA) and endothelial nitric oxide synthase (eNOS) gene expression.
Key findings: The chronotropic responses decreased in BDL/Saline and increased in BDL/Ator-7d group. The QTc interval, BNP, TNF-α, and MDA levels increased in BDL/Saline and decreased in BDL/Ator-14d group. The Nrf2 level did not change in BDL/Saline and increased in BDL/Ator-14d group. The liver inflammation and fibrosis increased in BDL/Saline and did not affect BDL/Ator-7d and BDL/Ator-14d groups. The RhoA expression was down-regulated in BDL/Saline, BDL/Ator-7d, and BDL/Ator-14d groups. The eNOS expression did not change in BDL/Saline and down-regulated in BDL/Ator-14d group.
Significance: Atorvastatin alleviates the chronotropic hypo-responsiveness and down-regulates the atrial RhoA and eNOS gene expression along with anti-inflammatory, antioxidant, and anti-stress effects in CCM.
Keywords: Atorvastatin; Bile duct ligation (BDL); Chronotropic responses; Cirrhotic cardiomyopathy (CCM); Endothelial nitric oxide synthase (eNOS); Ras homolog family member A (RhoA).
Copyright © 2022. Published by Elsevier Inc.
Conflict of interest statement
Conflict of interest statement The authors declare no conflicts of interest related to this work or its publication.
Similar articles
-
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.Hepatology. 2007 Jul;46(1):242-53. doi: 10.1002/hep.21673. Hepatology. 2007. PMID: 17596891
-
Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity.Biomed Pharmacother. 2014 Feb;68(1):101-10. doi: 10.1016/j.biopha.2013.09.001. Epub 2013 Oct 8. Biomed Pharmacother. 2014. PMID: 24268999
-
A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.Sci Rep. 2017 Jan 13;7:40461. doi: 10.1038/srep40461. Sci Rep. 2017. PMID: 28084470 Free PMC article.
-
Evaluation of the effect of heat shock protein 70 targeted drugs on cirrhotic cardiomyopathy in biliary cirrhotic rats.Life Sci. 2021 May 15;273:119261. doi: 10.1016/j.lfs.2021.119261. Epub 2021 Feb 27. Life Sci. 2021. PMID: 33652036
-
Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection.Expert Rev Neurother. 2009 Aug;9(8):1171-86. doi: 10.1586/ern.09.70. Expert Rev Neurother. 2009. PMID: 19673606 Free PMC article. Review.
Cited by
-
Therapies for Cirrhotic Cardiomyopathy: Current Perspectives and Future Possibilities.Int J Mol Sci. 2024 May 28;25(11):5849. doi: 10.3390/ijms25115849. Int J Mol Sci. 2024. PMID: 38892040 Free PMC article. Review.
-
Recent advances in liver-on-chips: Design, fabrication, and applications.Smart Med. 2023 Feb 12;2(1):e20220010. doi: 10.1002/SMMD.20220010. eCollection 2023 Feb. Smart Med. 2023. PMID: 39188562 Free PMC article. Review.
-
Cardiomyopathy in cirrhosis: From pathophysiology to clinical care.JHEP Rep. 2023 Sep 23;6(1):100911. doi: 10.1016/j.jhepr.2023.100911. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38089549 Free PMC article. Review.
-
Effects of Gap 26, a Connexin 43 Inhibitor, on Cirrhotic Cardiomyopathy in Rats.Cureus. 2024 Apr 26;16(4):e59053. doi: 10.7759/cureus.59053. eCollection 2024 Apr. Cureus. 2024. PMID: 38680825 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous